This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Janet E. Pope, MD, MPH, FRCPC; Jennifer J. Anderson, PhD; David T. Felson, MD, MPH

Arch Intern Med. 1993;153(4):477-484.

Abstract
Background
Nonsteroidal anti-inflammatory drugs (NSAIDs) have well-known gastrointestinal and renal toxic reactions. Effects of NSAIDs on blood pressure are less appreciated. A meta-analysis was performed to determine the hypertensive effects of NSAIDs and rank them by magnitude of change in mean arterial pressure (MAP).

Methods
A literature search of published English-language studies of NSAIDs and their effects on blood pressure was done. Studies were included if they met the following criteria: (1) the studies were intervention studies; (2) NSAIDs at any dose or aspirin at doses of 1.5 g/d or greater were included; (3) documentation of blood pressure was provided; and (4) the studies were 24 hours in duration. Studies were excluded if 20% or more of their participants dropped out or if the dose of antihypertensive drugs was adjusted while the subjects were taking NSAIDs. The major outcome was change in MAP while patients were receiving NSAIDs. Each NSAID arm was extracted from its trial. Information on possible confounders, including subject age, trial quality, amount of dietary salt intake, and whether study subjects were hypertensive or normotensive, was recorded. We calculated the average change in MAP on each NSAID, adjusting for confounders.

Results
Fifty-four studies with 123 NSAID treatment arms met inclusion criteria. The mean age of subjects was 46 years. Of the 1324 participants, 1213 subjects (92%) were hypertensive. The effects of NSAIDs on blood pressure were found solely in hypertensive subjects. Among these, the increase in MAP after adjusting for amount of dietary salt intake was 3.59 mm Hg for indomethacin (57 treatment arms), 3.74 mm Hg for naproxen (four arms), and 0.49 mm Hg for piroxicam (four arms). The MAP decreased by 2.59 mm Hg for placebo (10 arms), 0.83 mm Hg for ibuprofen (six arms), 1.76 mm Hg for aspirin (four arms), and 0.16 mm Hg for sulindac (23 arms). The effects on MAP by using placebo, sulindac, and aspirin were statistically significantly different from indomethacin.

Conclusions
In short-term use, NSAIDs vary considerably in their effect on blood pressure. Of the drugs studied, indomethacin and naproxen were associated with the largest increases in blood pressure. The average effects of piroxicam, aspirin, ibuprofen, and sulindac were negligible.

(Arch Intern Med. 1993;153:477-484)

Author Affiliations
From the Arthritis Center at Boston (Mass) University, and the Departments of Medicine, Boston City and University Hospitals. Dr Pope is currently at the University of Western Ontario, London.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Salicylates dilate blood vessels through inhibiting PYK2-mediated RhoA/Rho-kinase activation
Ying et al.
Cardiovasc Res 2009;83:155-162.
ABSTRACT | FULL TEXT  

Pain management in patients with chronic kidney disease
Pham et al.
NDT Plus 2009;2:111-118.
ABSTRACT | FULL TEXT  

Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study)
Combe et al.
Rheumatology (Oxford) 2009;48:425-432.
ABSTRACT | FULL TEXT  

Hypertension in rheumatoid arthritis
Panoulas et al.
Rheumatology (Oxford) 2008;47:1286-1298.
ABSTRACT | FULL TEXT  

Review: Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema?
Aneja and Farkouh
Ther Adv Cardiovasc Dis 2008;2:53-66.
ABSTRACT  

A Risk Score for Predicting Near-Term Incidence of Hypertension: The Framingham Heart Study
Parikh et al.
ANN INTERN MED 2008;148:102-110.
ABSTRACT | FULL TEXT  

Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout
Willburger et al.
Rheumatology (Oxford) 2007;46:1126-1132.
ABSTRACT | FULL TEXT  

New Diagnosis of Hypertension Among Celecoxib and Nonselective NSAID Users: A Population-Based Cohort Study
Wang et al.
The Annals of Pharmacotherapy 2007;41:937-943.
ABSTRACT | FULL TEXT  

Mechanism for Covalent Binding of Rofecoxib to Elastin of Rat Aorta
Oitate et al.
J. Pharmacol. Exp. Ther. 2007;320:1195-1203.
ABSTRACT | FULL TEXT  

Cardiovascular Effects of the Cyclooxygenase Inhibitors
White
Hypertension 2007;49:408-418.
FULL TEXT  

Frequency of Analgesic Use and Risk of Hypertension Among Men
Forman et al.
Arch Intern Med 2007;167:394-399.
ABSTRACT | FULL TEXT  

COVALENT BINDING OF RADIOACTIVITY FROM [14C]ROFECOXIB, BUT NOT [14C]CELECOXIB OR [14C]CS-706, TO THE ARTERIAL ELASTIN OF RATS
Oitate et al.
Drug Metab. Dispos. 2006;34:1417-1422.
ABSTRACT | FULL TEXT  

NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland
Helin-Salmivaara et al.
Eur Heart J 2006;27:1657-1663.
ABSTRACT | FULL TEXT  

Differing Administration Time-Dependent Effects of Aspirin on Blood Pressure in Dipper and Non-Dipper Hypertensives
Hermida et al.
Hypertension 2005;46:1060-1068.
ABSTRACT | FULL TEXT  

Aspirin Administered at Bedtime, But Not on Awakening, Has an Effect on Ambulatory Blood Pressure in Hypertensive Patients
Hermida et al.
J Am Coll Cardiol 2005;46:975-983.
ABSTRACT | FULL TEXT  

Aspirin: A Novel Antihypertensive Drug?: Or Two Birds With One Stone?
Messerli
J Am Coll Cardiol 2005;46:984-985.
FULL TEXT  

Analgesic Use and Risk of Subsequent Hypertension in Apparently Healthy Men
Kurth et al.
Arch Intern Med 2005;165:1903-1909.
ABSTRACT | FULL TEXT  

Non-Narcotic Analgesic Dose and Risk of Incident Hypertension in US Women
Forman et al.
Hypertension 2005;46:500-507.
ABSTRACT | FULL TEXT  

Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study
Hudson et al.
BMJ 2005;330:1370.
ABSTRACT | FULL TEXT  

Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure
Aw et al.
Arch Intern Med 2005;165:490-496.
ABSTRACT | FULL TEXT  

The Effects of Cyclooxygenase-2 Inhibitors and Nonsteroidal Anti-inflammatory Therapy on 24-Hour Blood Pressure in Patients With Hypertension, Osteoarthritis, and Type 2 Diabetes Mellitus
Sowers et al.
Arch Intern Med 2005;165:161-168.
ABSTRACT | FULL TEXT  

Treating Osteoarthritis With Cyclooxygenase-2-Specific Inhibitors: What Are the Benefits of Avoiding Blood Pressure Destabilization?
Grover et al.
Hypertension 2005;45:92-97.
ABSTRACT | FULL TEXT  

Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei et al.
ANN INTERN MED 2004;141:764-770.
ABSTRACT | FULL TEXT  

Hypertension Associated With Therapies to Treat Arthritis and Pain
White
Hypertension 2004;44:123-124.
FULL TEXT  

Effects of COX Inhibition on Blood Pressure and Kidney Function in ACE Inhibitor-Treated Blacks and Hispanics
Izhar et al.
Hypertension 2004;43:573-577.
ABSTRACT | FULL TEXT  

Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance
Meune et al.
Journal of Renin-Angiotensin-Aldosterone System 2003;4:149-154.
ABSTRACT  

Cyclooxygenase-2 Inhibitors
Gajraj
Anesth. Analg. 2003;96:1720-1738.
FULL TEXT  

Administration Time-Dependent Effects of Aspirin on Blood Pressure in Untreated Hypertensive Patients
Hermida et al.
Hypertension 2003;41:1259-1267.
ABSTRACT | FULL TEXT  

Nonnarcotic analgesic use and the risk of hypertension
O'Brien
CMAJ 2003;168:1445-1445.
FULL TEXT  

Tackling ischaemic heart disease in rheumatoid arthritis
Kitas and Erb
Rheumatology (Oxford) 2003;42:607-613.
FULL TEXT  

Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors
Hawkey and Langman
Gut 2003;52:600-608.
ABSTRACT | FULL TEXT  

Effect of Cyclooxygenase-2 Inhibitors on Blood Pressure
Johnson et al.
The Annals of Pharmacotherapy 2003;37:442-446.
ABSTRACT | FULL TEXT  

Nonnarcotic Analgesic Use and the Risk of Hypertension in US Women
Dedier et al.
Hypertension 2002;40:604-608.
ABSTRACT | FULL TEXT  

Frequency of Analgesic Use and Risk of Hypertension in Younger Women
Curhan et al.
Arch Intern Med 2002;162:2204-2208.
ABSTRACT | FULL TEXT  

The Renal Effects of Traditional Nonsteroidal Anti-Inflammatory Agents Versus Cyclooxygenase-2 Inhibitors
Joy
Journal of Pharmacy Practice 2002;15:383-391.
ABSTRACT  

Effects of Celecoxib on Ambulatory Blood Pressure in Hypertensive Patients on ACE Inhibitors
White et al.
Hypertension 2002;39:929-934.
ABSTRACT | FULL TEXT  

Evidence based management of hypertension: What to do when blood pressure is difficult to control
O'Rorke and Richardson
BMJ 2001;322:1229-1232.
FULL TEXT  

Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients
Conlin et al.
Hypertension 2000;36:461-465.
ABSTRACT | FULL TEXT  

Optimising drug treatment for elderly people: the prescribing cascade
Rochon and Gurwitz
BMJ 1997;315:1096-1099.
FULL TEXT  

Use of nonsteroidal anti-inflammatory drugs in cancer
Pace
Palliat Med 1995;9:273-286.
ABSTRACT  

The Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressures of Patients With Hypertension Controlled by Verapamil
Houston et al.
Arch Intern Med 1995;155:1049-1054.
ABSTRACT  

High Blood Pressure: A Side Effect of Drugs, Poisons, and Food
Grossman and Messerli
Arch Intern Med 1995;155:450-460.
ABSTRACT  

Initiation of Antihypertensive Treatment During Nonsteroidal Anti-inflammatory Drug Therapy
Gurwitz et al.
JAMA 1994;272:781-786.
ABSTRACT